ClinicalTrials.gg
CompletedNCT01449188Updated Nov 13, 2017

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

A Phase 1 interventional study of ondansetron and moxifloxacin in Nausea and Vomiting, Chemotherapy-Induced, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-13.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing ondansetron in Nausea — 1 open to participants now, 1 under way, none of them phase 3. Ondansetron · Nausea.

Enrollment
28th of 46
60 · median 100
Started
2011
with 2 others
Phase 1
11 of 47
none open now
Registered
22nd of 47
by date
Lead sponsor
4 of 47
GlaxoSmithKline

Among the 47 studies testing ondansetron in Nausea, this one is the 28th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2011, is one of 11 in phase 1, and was the 22nd registered.

Nausea

644 studies on the registry are indexed under Nausea; 85 are open to participants now.

Browse Nausea studies →

Open to participants now

1 of the 47 studies testing ondansetron in Nausea is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ondansetron

Ondansetron: first FDA approval 1991 (ZOFRAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 51 Nausea studies recruiting now, 21 (41%) set no upper age limit and 19 (37%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing ondansetron in Nausea, or all of them as a file.
02

Study summary

Ondansetron, also known as Zofran, is a marketed compound used for the prevention of nausea and vomiting. This study, called a thorough QT study, will characterize the effects of a single intravenous (IV) dose of ondansetron on cardiac repolarization as compared to placebo. Moxifloxacin, a commercially available antibiotic known to cause a mild QT prolongation, will be used as a positive control and will be given orally. The cardiac repolarization will be measured by taking consecutive ECGs on a recording device known as a Holter monitor and measuring the QT interval at specified times. In addition, blood samples will also be taken at specified times and will be used to measure the amount of study medication in the body.

Read the detailed description

Ondansetron was first approved in 1991 for treatment of nausea and vomiting associated with chemotherapy and surgical procedures and as ondansetron was developed prior to current regulatory requirements, a formal, thorough QT study has not been performed for this compound. The purpose of this study is to further define the safety of ondansetron as some effects on QT interval prolongation have been observed for this and other members of the 5-HT3 inhibitor class of compounds. In the case of ondansetron, these effects have been rare and transient and noted primarily with IV administration, however, the extent to which ondansetron prolongs the QT interval has not been defined.

This study will quantify the effects of a single dose of IV ondansetron administered over 15 minutes on cardiac conduction in a double-blind, cross-over study and compared to placebo and a positive control, oral moxifloxacin. Pre- and post-dose digital electrocardiograms (ECGs) will be obtained by continuous Holter monitoring (1000 Hz) for blinded over-read by a third party vendor. This double-blind study will randomize approximately 60 healthy adult male and female volunteers to one of 12 sequences each consisting of 4 study treatment periods in a crossover design with a 7-day washout between each treatment period. Subjects will receive placebo, moxifloxacin (single 400 mg tablet), ondansetron 8 mg, and ondansetron 32 mg based on the randomized sequence. Both ondansetron and the placebo for ondansetron will be administered intravenously over 15 minutes. Moxifloxacin, a drug known to cause mild QTc prolongation, is included as a positive control and will be dosed as open label. Serial blood samples will be obtained to determine ondansetron and, if needed, moxifloxacin pharmacokinetic parameters. Safety and tolerability will be assessed through physical exams, adverse events, concurrent medications, clinical laboratory tests and vital signs.

03

Conditions studied

  • Nausea and Vomiting, Chemotherapy-Induced

Browse trials for

Keywords

  • ondansetron
  • moxifloxacin
  • Zofran
  • thorough QT study
  • IV
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult men and women, non-smokers between 18 and 45 years of age inclusive, at the time of signing the . Every effort will be made to enrol an approximately equal number of males and females.
  • Signed and dated written informed consent prior to admission to the study, which includes compliance with the requirements and restrictions listed in the consent form.
  • Healthy as judged by a responsible physician, with no abnormality identified on the medical or laboratory evaluation performed at Screening, including 12-lead . A subject with a clinical abnormality or laboratory parameters outside the reference range for this age group may be included only with the approval of the GSK medical monitor.
  • , alkaline phosphatase and less than or equal to 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • A female is eligible to enter and participate in this study if she is of: Non- (i.e., physiologically incapable of becoming pregnant), including any female who either has had a hysterectomy or has had a bilateral oophorectomy (ovariectomy) or is defined as being amenorrhoeic for greater than or equal to 1 year with an appropriate clinical profile, e.g., age appropriate, history of vasomotor symptoms. Follicle-stimulating hormone (FSH) must be greater than or equal to 40 mIU/mL to confirm the post-menopausal state.

If a female is of child-bearing potential, has a negative serum pregnancy test at Screening, and agrees to or has undergone one of the following: Complete abstinence from sexual intercourse from 2 weeks prior to administration of the study drug until completion of the follow-up procedures, or, bilateral tubal ligation, or have a vasectomized partner or use an intrauterine device with published data showing that expected failure rate is less than 1% per year (e.g., GynaeFix) from 2 weeks prior to administration of study drug until completion of the follow-up procedures, or, use double-barrier method [condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/cream/suppository].

  • (BMI)* in the range of 19 - 30 kg/m2 (inclusive). *[BMI = weight [kg]/(height [m])2]

Exclusion criteria

Exclusion Criteria:

  • Cardiac conduction abnormalities denoted by any of the following at screening:

> 450 msec; PR interval > 240 msec or less than or equal to 110 msec; evidence of second- or third-degree atrioventricular (AV) block; pathological Q-waves (defined as Q-wave > 40 msec or depth greater than 0.4 - 0.5 mV); evidence of ventricular pre-excitation; electrocardiographic evidence of complete left bundle branch block, right bundle branch block (RBBB), incomplete LBBB; intraventricular conduction delay with QRS duration > 120 msec; bradycardia as defined by sinus rate \< 50 bpm.

  • Any history of myocardial infarction, syncope, long-QT syndrome, cardiac arrhythmias, or a history of uncontrolled hypertension or unstable heart disease within the 6 months prior to the screening visit, or a family history of long-QT syndrome or a family history of sudden death.
  • Family history of heart attack or stroke at age less than or equal to 60 years.
  • Levels of potassium, magnesium, and calcium outside the normal reference range at screening.
  • serum chemistry and complete blood count parameters outside the normal reference range at screening.
  • Positive for antibody, virus S-antigen (HbSAg) or (Hep C) virus antibody at screening.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • History of alcohol/drug abuse or dependence within 12 months of the study.
  • History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
  • A positive pre-study urine test for drugs of abuse including alcohol at screening or prior to the start of dosing. A minimum list of drugs that will be screened for includes amphetamines, barbiturates, cocaine, opiates, cannabinoids, benzodiazepines, and cotinine. Subjects will be re-screened at each treatment period.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK medical monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • The subject has donated blood or blood products in excess of 500 mL within a 56 day period.
  • Pregnant females as determined by positive serum hCG test at screening.
  • Consumption of aspirin, aspirin-containing compounds, salicylates or nonsteroidal anti-inflammatory agents (NSAIDs) within 14 days of the study start and until the end of the follow-up visit. Acetaminophen (less than or equal to 2 g/day) will be permitted during the study for analgesia.
  • Subject has consumed liquid antacids (e.g., Maalox, Mylanta, Amphojel, Milk of Magnesia) or chewable antacids (e.g., TUMS™) within 48 hours of the first dose of study medication, and throughout the duration of study drug administration.
  • History of sensitivity to moxifloxacin or any member of the quinolone class of antimicrobial agents, or history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation. If use of an IV cannula with heparinized flush is anticipated for PK draws, then to heparin is also exclusionary.
  • Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • Consumption of red wine, seville oranges, grapefruit or grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    ondansetron, 8 mg IV over 15 minutes

    the lower ondansetron IV dose will be used in one of the four treatment periods

    Drug: ondansetron

  • Active comparator
    ondansetron, 32 mg IV over 15 minutes

    the higher ondansetron IV dose will be used in one of the four treatment periods

    Drug: ondansetron

  • Placebo comparator
    placebo for ondansetron, IV over 15 minutes

    placebo for ondansetron IV dose will be used in one of the four treatment periods

    Other: saline

  • Active comparator
    moxifloxacin, 400mg tablet (oral)

    moxifloxacin is known to produce mild QT prolongation and will be used in one of the four treatment periods

    Drug: moxifloxacin

Interventions

  • FDA approved drug used to treat nausea and vomiting

    Also known as: Zofran

  • FDA approved antibiotic commonly used as a positive control in thorough QT studies

    Also known as: Avelox

  • Othersaline

    USP saline IV solution used as placebo for ondansetron IV.

06

What researchers measure

Primary outcomes

  1. Change in QTcF after a single dose of Ondansetron given IV over 15 minutes.

    Two doses of ondansetron willl be used, 8mg and 32mg. The change in QTcF will be time-matched, baseline adjusted and compared to placebo.

    Time frame: Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

Secondary outcomes

  1. characterize relationship between changes in ddQTc and plasma concentrations of ondansetron

    The slope of the relationship between ddQTc and plasma ondansetron concentrations and predicted change in ddQtc will be used to determine.

    Time frame: Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

  2. characterize relationship between QT interval and plasma ondansetron

    The slope of the relationship between QTc interval and ondansetron concentrations and predicted change in QTc from baseline will be used to determine.

    Time frame: Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

  3. characterize the effect on QTcI and QTcB relative to placebo between the two doses of ondansetron and moxifloxacin

    ECG parameters will be measured and used to calculate this effect.

    Time frame: Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

  4. characterize effect on QT and HR relative to placebo of the two doses of ondansetron and moxifloxacin.

    ECG parameters will be measured along with vitals and used to calculate this effect.

    Time frame: Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

  5. characterize the pharmacokinetics of ondansetron.

    plasma concentrations of ondansetron will be measured and PK parameters (AUC, Cmax, tmax) determined.

    Time frame: Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

  6. characterize safety and tolerability of the two doses of ondansetron.

    Tolerability and safety will be assessed by 12-lead ECGs, telemetry, BP, HR, Adverse Events and clinical laboratory tests.

    Time frame: Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

  7. characterize the pharmacokinetics of moxifloxacin if needed.

    plasma concentrations of moxifloxacin will be measured and PK parameters (AUC, Cmax, tmax) determined if needed.

    Time frame: Single dosing day at each of the 4 treatment periods with a 7-day washout between each period. The total duration of each subject's participation in the study, from screening through follow-up will be an average of 11 weeks.

07

Study locations

1 site
  • GSK Investigational Site
    Austin, Texas 78744, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2011 to primary completion in Dec 2011, 4 months.

Of 18 phase 1 interventional studies under Nausea, half reached primary completion within 4 months of starting (the median); a quarter within 2 and three quarters within 8. This study's 4 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2011
First posted
Oct 10, 2011
StartActual
Aug 16, 2011
Primary completionActual
Dec 19, 2011
CompletionActual
Dec 19, 2011
Last update
Nov 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01449188
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 10, 2011
Start date
Aug 16, 2011
Primary completion
Dec 19, 2011
Completion
Dec 19, 2011
Last update
Nov 13, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ondansetron · Moxifloxacin

Start the discussion